Federal Funding Opportunities

US Navy Summer Faculty Research Program and Sabbatical Leave Program http://www.onr.navy.mil/Education-Outreach/Summer-Faculty-Research-Sabbatical.aspx

Biology

BioChemistry

NIH mechanisms by which Brandeis researchers are currently funded (from https://projectreporter.nih.gov):

- DP2
- F31 (Predoctoral Individual National Research Service Award) (aka predoc NRSA)
- F32 (Postdoctoral Individual National Research Service Award) (aka postdoc NRSA)
- K01 (Mentored Research Scientist Career Development Award)
- K99/R00 (Pathway to Independence Award)
- P01 (Program Project/Center Grants)
- P30
- R01 (Research Project Grants)
- R03 (NIH Small Grant Program)
- R21
- R34
- R37
- R56
- R90/T90
- T32 (Institutional Training Grants)
- U01

Other NIH mechanism applied for, or held in the past

- F99/K00
- R25 (Research Education Program) (an umbrella of many different kinds of programs)

NSF Opportunities (selected)

- Faculty Early Career Development Program (CAREER) | FAQ
- NSF Graduate Research Fellowship Program (GRFP)

Chemistry


CoSci


Math

Physics


Some links

- Search grants.gov
- NIH Funding Opportunities and Notices
- DOE Funding Opportunities

Some links

- Search grants.gov
- NIH Funding Opportunities and Notices
- DOE Funding Opportunities
## Opportunities and Policy Notices from the National Institutes of Health

| Notice to Specify High-Priority Research Topics for PAR-19-070 and PAR-19-071 |
| Notice NOT-AG-18-048 from the NIH Guide for Grants and Contracts |
| Notice to Specify High-Priority Research Topic for PAR-19-070 |
| Notice NOT-AG-18-049 from the NIH Guide for Grants and Contracts |
| Notice to Specify High-Priority Research Topic for PAR-19-070 |
| Notice NOT-AG-18-050 from the NIH Guide for Grants and Contracts |
| Notice to Specify High-Priority Research Topic for PAR-19-070 |
| Notice NOT-AG-18-051 from the NIH Guide for Grants and Contracts |
| Request for Information (RFI): Epidemiology of Opioid Use and Consequences- What is needed to understand and solve the crisis |
| Notice NOT-DA-19-007 from the NIH Guide for Grants and Contracts |
| Notice of NIDCD’s Withdrawal from Participation in PA-19-055 "Research Project Grant (Parent R01 Clinical Trial Required)" |
| Notice NOT-DC-19-003 from the NIH Guide for Grants and Contracts |
| Notice of Extension of Expiration Date for PAR-16-070 NIDCR Small Research Grants for Data Analysis and Statistical Methodology Applied to Genome-wide Data (R03) |
| Notice NOT-DE-18-030 from the NIH Guide for Grants and Contracts |
| Notice to Update Certificates of Confidentiality Terms and Conditions on all FDA Funding Opportunity Announcements and Grant Awards |
| REMINDER - Expiring Funds Alert to AHRQ Grant Recipients who Received Multi-Year Funded Awards Notice NOT-HS-19-002 from the NIH Guide for Grants and Contracts |
| Reminder to AHRQ Grantees that FY2014 Funds will Expire on September 30, 2019 Notice NOT-HS-19-003 from the NIH Guide for Grants and Contracts |
| Ruth L. Kirschstein National Research Service Award (NRSA) Stipends, Tuition/Fees and Other Budgetary Levels Effective for Fiscal Year 2019 Notice NOT-OD-19-036 from the NIH Guide for Grants and Contracts |
**Findings of Research Misconduct**
Notice NOT-OD-19-037 from the NIH Guide for Grants and Contracts

**Notice of Intent to Publish a Funding Opportunity Announcement for Diversity Program Consortium Sponsored Programs Administration Development (SPAD) Program (G11)**

**Alcohol-HIV/AIDS Program Project (P01 Clinical Trial Optional)**
Funding Opportunity
RFA-AA-19-002 from the NIH Guide for Grants and Contracts. Through this FOA, NIAAA seeks to encourage research that can be translated into interventions in order to reduce infection and transmission of HIV. These critical goals are consistent with the FY2013 Trans-NIH Plan For HIV-Related Research (http://www.oar.nih.gov/strategicplan/fy2013/index.asp).

**Exploring Molecular Links Between Dietary Interventions and Circadian Rhythm (R01 Clinical Trial Not Allowed)**
Funding Opportunity
RFA-AG-19-029 from the NIH Guide for Grants and Contracts. This FOA encourages innovative experimental approaches to explore how dietary intervention entrains peripheral or central clocks to maintain tissue homeostasis and how circadian regulation integrates with various dietary strategies to achieve optimal health benefits.

**Genetic Engineering Technologies for HIV Cure Research (U19 Clinical Trial Optional)**
Funding Opportunity
RFA-AI-18-058 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to apply genetic engineering technologies to HIV-1 cure research. Gene- and/or cell-based approaches are sought that can achieve
long term remission of HIV-1 in the absence of antiretroviral treatment or complete elimination of HIV-1. Applications are expected to include basic science/preclinical research as well as translational activities such as test-of-concept studies in animal models or human subjects and must be designed as collaborative efforts between academia and the private sector.

### Support for Small Business Innovation Research to Develop New Open and Closed-Loop Automated Technologies for Better Type 1 Diabetes Therapy and Monitoring (SBIR) (R43/R44 Clinical Trial Not Allowed)

Funding Opportunity RFA-DK-18-022 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to stimulate bioengineers, physiologists, bio-behavioral researchers, and designers in academic centers and small businesses to develop new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies including open and closed loop hormone replacement systems.

### A Practice-Based Research Network to Transform Mental Health Care: Science, Service Delivery and Sustainability (U19 Clinical Trial Required)

Funding Opportunity RFA-MH-19-225 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support a practice-based research network in the United States to transform the development, delivery, and sustainability of evidence-based mental health practices and services. Through a research consortium embedded within large and integrated healthcare delivery systems (public and/or commercial systems) that serve representative populations, this Network would result in a
continuously learning healthcare system as defined by the Institute of Medicine, to create a continuous cycle or feedback loop in which scientific evidence informs clinical practice while data gathered from clinical practice and administrative sources inform scientific investigation.

**Promoting Reductions in Intersectional Stigma (PRISM) to Improve the HIV Prevention Continuum (R34 Clinical Trial Required)**

Funding Opportunity RFA-MH-19-410 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits research grant applications which will: 1) advance measurements of intersectional stigma (multiple stigmatized identities) and examine the mechanisms and pathways by which it is a barrier to HIV testing and linkage to prevention; or 2) develop and test interventions to reduce intersectional stigma and improve the uptake of HIV testing and linkage to ongoing HIV prevention among key populations at substantial risk for HIV infection.

**Promoting Reductions in Intersectional Stigma (PRISM) to Improve the HIV Prevention Continuum (R21 Clinical Trial Optional)**

Funding Opportunity RFA-MH-19-411 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits research grant applications which will: 1) advance measurements of intersectional stigma (multiple stigmatized identities) and examine the mechanisms and pathways by which it is a barrier to HIV testing and linkage to prevention; or 2) develop and test interventions to reduce intersectional stigma and improve the uptake of HIV testing and linkage to ongoing HIV prevention among key populations at substantial risk for HIV infection.

RFA-MH-19-412 uses the R01 grant mechanism, and
RFA-MH-19-410 uses the R34 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants with preliminary data and/or include longitudinal analysis may be appropriate for the R01 mechanism. Applicants proposing to develop and pilot test an intervention should consider using the R34 mechanism.

**Promoting Reductions in Intersectional Stigma (PRISM) to Improve the HIV Prevention Continuum (R01 Clinical Trial Optional)**

Funding Opportunity RFA-MH-19-412 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits research grant applications which will: 1) advance measurements of intersectional stigma (multiple stigmatized identities) and examine the mechanisms and pathways by which it is a barrier to HIV testing and linkage to prevention; or 2) develop and test interventions to reduce intersectional stigma and improve the uptake of HIV testing and linkage to ongoing HIV prevention among key populations at substantial risk for HIV infection.

**Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 Clinical Trial Not Allowed)**

Funding Opportunity RFA-OD-19-012 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this OBSSR and participating institutes and centers R25 program is to support educational activities that develop cross-cutting methodologies and analytics that are needed to more rapidly advance behavioral and social sciences research (BSSR) and are not already well addressed.
by existing educational programs widely available to the research community. Methodological domains of focus include but are not limited to innovative data collection methodologies and analytic techniques, analysis and linking of big data, or needed but underused designs to advance research across the translational spectrum. Priority will be given to courses that address an important and cross-cutting educational need, that fill a gap in the field not already well addressed by other opportunities and that include a plan for increased reach and sustainability of the training both during and beyond the funding period. Over the period of support, it is expected that the course will be refined, improved, and sufficiently well-documented and resourced for dissemination of the program when the period of support ends. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development.

**Specialized Centers of Research Excellence (SCORE) on Sex Differences (US4 Clinical Trial Optional)**
Funding Opportunity RFA-OD-19-013 from the NIH Guide for Grants and Contracts. The ORWH and participating organizations and institutes seek applications for Specialized Centers of Research Excellence (SCORE) on Sex Differences. The Centers of Excellence will support interdisciplinary approaches to advance translational research on sex differences. Each SCORE institution should develop a research agenda bridging basic and clinical research underlying a health issue that is pertinent to improving the health of women.

**Enabling Technologies to Accelerate Development of Oral Biodevices (R41/R42 Clinical Trial Not Allowed)**
Funding Opportunity PA-19-075
from the NIH Guide for Grants and Contracts. Purpose This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors, associated core technologies and integrated approaches that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors, associated core technologies and integrated approaches that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

**Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed)**

Funding Opportunity PA-19-077 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support early phase translational research that will generate new malaria vaccine candidates suitable for further downstream development and
Clinical evaluation. This research opportunity encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially P. falciparum and P. vivax.

**Advancing Development of Rapid Fungal Diagnostics (R01 Clinical Trial Not Allowed)**
Funding Opportunity PA-19-080 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support the development of rapid, sensitive, specific, simple, and cost-effective diagnostics for primary health-care settings (hospitals and point-of-care).

**Advancing Development of Rapid Fungal Diagnostics (R21 Clinical Trial Not Allowed)**
Funding Opportunity PA-19-081 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support the development of rapid, sensitive, specific, simple, and cost-effective diagnostics for primary health-care settings (hospitals and point-of-care).

**Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R01 Clinical Trial Not Allowed)**
Funding Opportunity PA-19-082 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis. This research opportunity encourages studies that address diverse scientific areas such as: 1) pathogenesis; 2) host response; 3) disease transmission; 4) natural history and environmental factors contributing to disease; 5)
<table>
<thead>
<tr>
<th>Vaccines; 6) Diagnostics; and 7) Therapeutics; with the ultimate goal of advancing the field towards solutions for the improved detection, prevention and treatment of select endemic mycoses.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R21 Clinical Trial Not Allowed)</strong></td>
</tr>
<tr>
<td>Funding Opportunity PA-19-083 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis. This research opportunity encourages studies that address diverse scientific areas such as: 1) Pathogenesis; 2) host response; 3) disease transmission; 4) natural history and environmental factors contributing to disease; 5) vaccines; 6) diagnostics; and 7) therapeutics; with the ultimate goal of advancing the field towards solutions for the improved detection, prevention and treatment of select endemic mycoses.</td>
</tr>
<tr>
<td><strong>Mentored Research Scientist Development Award (Parent K01 - Independent Basic Experimental Studies with Humans Required)</strong></td>
</tr>
<tr>
<td>Funding Opportunity PA-19-084 from the NIH Guide for Grants and Contracts. The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to</td>
</tr>
</tbody>
</table>
research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity. This Funding Opportunity Announcement is designed specifically for applicants proposing to lead basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion Clinical Trials Required FOA.

**Independent Scientist Award (Parent K02 - Independent Basic Experimental Studies with Humans Required)**

Funding Opportunity PA-19-085 from the NIH Guide for Grants and Contracts. The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and “protected time” for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each
independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to lead basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion PA-18-370.

*Mentored Clinical Scientist Research Career Development Award (Parent K08 - Independent Basic Experimental Studies with Humans Required)*

Funding Opportunity PA-19-086 from the NIH Guide for Grants and Contracts. The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is
designed specifically for applicants proposing to lead basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion PA-18-372.

**Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)**

Funding Opportunity PA-19-087 from the NIH Guide for Grants and Contracts. The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to lead basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to
conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion PA-18-375.

Midcareer Investigator Award in Patient-Oriented Research (Parent K24 - Independent Basic Experimental Studies with Humans Required)

Funding Opportunity PA-19-088 from the NIH Guide for Grants and Contracts. The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors primarily for clinical residents, clinical fellows and/or junior clinical faculty. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to lead basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should
submit under the companion PA-18-393.

**Mentored Quantitative Research Development Award (Parent K25 - Independent Basic Experimental Studies with Humans Required)**

Funding Opportunity PA-19-089 from the NIH Guide for Grants and Contracts. The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to lead basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion PA-18-395.
NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)

Funding Opportunity PA-19-090 from the NIH Guide for Grants and Contracts. The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to lead basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion PA-18-397.

NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
Funding Opportunity PA-19-091 from the NIH Guide for Grants and Contracts. The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trials Required FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
Funding Opportunity PA-19-092 from the NIH Guide for Grants and Contracts. The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a
major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trials Required or Clinical Trial Optional FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

**Emotion Regulation, Aging and Mental Disorder (R01 Clinical Trial Not Allowed)**

Funding Opportunity PA-19-094 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. If older
adults who suffer episodes of affective dysregulation share the same patterns of improved emotional function with age as have been found to be typical of the older adult population in general. Research that helps to clarify whether they do or do not manifest typical emotion processing trajectories may lead to very different understanding of the irregularities involved their dysregulation. It is anticipated that such studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention strategies might be optimally applied to normalize emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle.

**Emotion Regulation, Aging and Mental Disorder (R21 Clinical Trial Not Allowed)**

Funding Opportunity PA-19-095 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. If older adults who suffer episodes of affective dysregulation share the same patterns of improved emotional function with age as have been found to be typical of the older adult population in general, understanding of the irregularities involved their dysregulation. It is anticipated that such studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention
strategies might be optimally applied to normalize emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle.

<table>
<thead>
<tr>
<th>Control of Sexually Transmitted Infections (STIs) Through a Comprehensive Understanding of the Natural History of Infection (R01 Clinical Trial Not Allowed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding Opportunity PA-19-096 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research to advance the understanding of natural history of infection for three sexually transmitted infections (STIs): gonorrhea, syphilis, and chlamydia. This research opportunity encourages studies that address the natural history of infection in the context of either: 1) correlates of protection, 2) host response to infection, 3) clinical endpoints of disease, or 4) biological and clinical factors that influence clearance rather than persistence of infection.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding Opportunity PAR-19-078 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.</td>
</tr>
</tbody>
</table>
The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.

Leveraging Health Information Technology (Health IT) to Address Minority Health and Health Disparities (R01 Clinical Trial Optional)
Funding Opportunity PAR-19-093 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to support research that examines how health information technology adoption impacts minority health and health disparity populations in access to care, quality of care, patient engagement, and health outcomes.

Research to Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-infection (R01 Clinical Trial Not Allowed)
Funding Opportunity PAS-19-097 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving hepatitis B virus (HBV) cure in the presence or absence of human immunodeficiency virus (HIV).